UBS lowered the firm’s price target on QuidelOrtho (QDEL) to $29 from $45 and keeps a Neutral rating on the shares. Margins are on track and guidance was reaffirmed amid a smaller-than-expected impact from tariffs, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QDEL:
- QuidelOrtho Reports Strong Q1 2025 Financial Results
- Closing Bell Movers: Arm sinks over 10% as guidance falls short
- QuidelOrtho says will be taking price on a ‘selective basis as we can’
- QuidelOrtho says capital allocation priority remains paydown of debt
- QuidelOrtho says company actions ‘sufficient’ to mitigate tariff impacts